The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: PRMT5
Cancer drug shows promise targeting genetic weakness in some tumors, comments Virginia Tech expert
In an invited commentary, Kathleen Mulvaney, assistant professor with the Fralin Biomedical Research Institute at VTC, talks about the potential of a new drug that has shown early promise in clinical trials for solid tumors by killing cancer cells that lack specific tumor suppressor genes.